Suicidal Ideation and Behavior
- Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ.
- Prior to prescribing, weigh potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal thoughts and behavior should be referred to a mental health professional, as appropriate.
- Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.
- SILIQ is available only through a restricted program called the SILIQ REMS Program.
Approved Risk Evaluation and Mitigation Strategies (REMS)
Patient Counseling Information
Updated January 2018